Cognitive ability and metabolic physical health in first-episode psychosis.
Body mass index
Cognition
First episode psychosis
Heart rate
Lipids
Metabolic syndrome
Journal
Schizophrenia research. Cognition
ISSN: 2215-0013
Titre abrégé: Schizophr Res Cogn
Pays: United States
ID NLM: 101632223
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
11
11
2020
revised:
14
01
2021
accepted:
27
01
2021
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
5
3
2021
Statut:
epublish
Résumé
Cognitive impairments are a core feature of first-episode psychosis (FEP), arising before illness onset and antipsychotic exposure. Individuals with chronic psychosis experience poorer physical health while taking antipsychotic medication, but health disparities may be evident at FEP onset, prior to antipsychotic exposure. Given the links between cognition and physical health in healthy populations, the aim was to explore whether cognition and physical health are associated in FEP, which could inform early physical health interventions for cognition in FEP. Participants were aged 15 to 25 and included 86 individuals experiencing FEP with limited antipsychotic exposure and duration of untreated psychosis of ≤six months, and 43 age- and sex-matched controls. Individuals with FEP performed significantly poorer than controls in most cognitive domains (Cohen's
Identifiants
pubmed: 33659191
doi: 10.1016/j.scog.2021.100194
pii: S2215-0013(21)00001-9
pmc: PMC7895837
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100194Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
MB has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Astra Zeneca, Lundbeck, Merck, Pfizer, and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Lundbeck Merck, Pfizer and Servier – all unrelated to this work. In the past 3 years, CP served on an advisory board for Lundbeck, Australia Pty Ltd. He has received honoraria for talks presented at educational meetings organized by Lundbeck. He received a grant from Lundbeck Foundation. His work is funded by grants and fellowship from the National Health & Medical Research Council (NHMRC) of Australia. The authors have declared that there are no conflicts of interest in relation to the subject of this study.
Références
Diabetologia. 2008 Mar;51(3):436-43
pubmed: 18204831
Ann Gen Psychiatry. 2017 Feb 15;16:12
pubmed: 28289436
Neuropsychology. 2009 May;23(3):315-36
pubmed: 19413446
Arch Gen Psychiatry. 2011 Jun;68(6):609-16
pubmed: 21300937
Psychiatry Res. 2014 Nov 30;219(3):420-5
pubmed: 24999174
Front Psychiatry. 2018 Nov 13;9:580
pubmed: 30483163
Neurosci Biobehav Rev. 2016 Jun;65:185-94
pubmed: 27073049
Psychol Med. 2019 Feb;49(3):431-439
pubmed: 29729687
PLoS One. 2013 Jun 20;8(6):e66299
pubmed: 23840437
Psychol Med. 2015 Jan;45(1):1-9
pubmed: 25065902
Int J Obes (Lond). 2014 Apr;38(4):494-506
pubmed: 23913029
Appetite. 2013 Apr;63:119-28
pubmed: 23291218
Lancet Psychiatry. 2019 Aug;6(8):675-712
pubmed: 31324560
Prog Cardiovasc Dis. 2009 Jul-Aug;52(1):11-9
pubmed: 19615488
BMC Public Health. 2014 May 27;14:510
pubmed: 24885250
J Psychiatr Res. 2018 Apr;99:151-158
pubmed: 29454222
Schizophr Res. 2019 Jun;208:420-429
pubmed: 30685395
Psychol Med. 2020 Jul;50(9):1539-1547
pubmed: 31288867
Neuropsychol Rev. 2018 Dec;28(4):509-533
pubmed: 30343458
BMJ. 2000 May 6;320(7244):1240-3
pubmed: 10797032
Proc Nutr Soc. 2017 Nov;76(4):443-454
pubmed: 28889822
JAMA Psychiatry. 2016 Dec 1;73(12):1268-1275
pubmed: 27784035
Neuropsychologia. 2002;40(3):302-16
pubmed: 11684163
Neurobiol Aging. 2005 Dec;26 Suppl 1:42-5
pubmed: 16257476
Schizophr Res. 2014 Sep;158(1-3):156-62
pubmed: 25086658
Psychiatry Res. 2007 May 30;151(1-2):155-7
pubmed: 17376539
Lancet Psychiatry. 2015 Aug;2(8):726-742
pubmed: 26249304
Acta Psychiatr Scand. 2016 Apr;133(4):289-97
pubmed: 26558719
Schizophr Res. 2007 Jul;93(1-3):90-8
pubmed: 17478082
Bipolar Disord. 2014 Jun;16(4):422-31
pubmed: 24725166
Schizophr Res. 2011 Mar;126(1-3):257-64
pubmed: 20828991
Psychol Med. 2018 Oct;48(13):2247-2256
pubmed: 29331153
Psychiatry Res. 2018 Jan;259:350-357
pubmed: 29120842
Front Psychiatry. 2017 Apr 20;8:55
pubmed: 28473776
Early Interv Psychiatry. 2019 Aug;13(4):953-960
pubmed: 30024100
Front Psychiatry. 2018 Dec 03;9:642
pubmed: 30559684
Dis Model Mech. 2012 Sep;5(5):614-20
pubmed: 22915023
Psychol Med. 2016 Nov;46(15):3219-3230
pubmed: 27604840
Neuropsychiatr Dis Treat. 2019 Jul 22;15:2087-2099
pubmed: 31413575
West J Med. 2001 Nov;175(5):329-32
pubmed: 11694483
Pediatrics. 2012 Oct;130(4):e856-64
pubmed: 22945407
Obes Rev. 2011 Sep;12(9):740-55
pubmed: 21991597
Front Nutr. 2017 Oct 31;4:51
pubmed: 29164126
Schizophr Res. 2011 Sep;131(1-3):231-4
pubmed: 21724373
Acta Psychiatr Scand. 2000 Apr;101(4):323-9
pubmed: 10782554
J Clin Psychiatry. 2017 Sep/Oct;78(8):e1035-e1046
pubmed: 28102978
Neuropsychology. 2017 Oct;31(7):787-797
pubmed: 28368139
Early Interv Psychiatry. 2016 Jun;10(3):267-76
pubmed: 25721464
Psychosomatics. 2008 Mar-Apr;49(2):123-31
pubmed: 18354065
Compr Psychiatry. 2018 Oct;86:119-122
pubmed: 30118994
Psychiatry Res. 2018 Dec;270:547-553
pubmed: 30343240